Poor treatment options spur innovative research strategies By Polly Clayden, HIV i-Base Pediatric Drug Development Considerations: Pharmacokinetics There is an old adage in pediatric medicine: children are not little adults. This is particularly true when it comes to tuberculosis, for…
Gilead’s greed gives rise to a slew of advocacy priorities By Tracy Swan Activists are decrying Gilead’s refusal to continue codeveloping a winning HCV drug combination with Bristol-Myers Squibb (BMS), opting instead to focus on co-formulations of its own promising…
Preparing to defend and reshape a still-critical program By Coco Jervis An increasing demand for services, coupled with significant fiscal retrenchment among federal and state agencies, leaves the Ryan White HIV/AIDS CARE Act-funded program at a crossroads. But advocacy strategies…
By Mark Harrington Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and…
by Karyn Kaplan The current standard of care for HCV is pegylated interferon (PEG-IFN) and ribavirin. Yet in most countries, this treatment is unaffordable to all but the wealthiest people. In order to stimulate price reductions and increase access, Médecins…
by Erica Lessem December 28, 2012, was a historic day for the one million people around the world with strains of tuberculosis (TB) that are particularly difficult to treat. For the first time in forty years, the United States Food…
by Erica Lessem The world has recently called for zero new TB deaths, infections, and suffering, and that voice has been heard. Treatment Action Group (TAG), along with other activists, researchers, clinicians, implementers, policy makers, and foundation and government staff…
by Tim Horn Fact: If we’re going to make headway in preventing and treating non-AIDS-related health complications among people with HIV, which are very much on the rise and a serious risk to disease-free survival, we’re going to need the…
by Tracy Swan It is difficult not to be dazzled by cure rates of up to 100% from interferon-free hepatitis C virus (HCV) trials presented at the American Association for the Study of Liver Diseases (AASLD) meeting in November 2012.…